Recent studies have focused on the intersection of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopamine communication. While GLP activators are increasingly employed for treating type 2 T2DM, their emerging impacts on reinforcement circuits, specific